|
Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery Clinical research trials and Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery. Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery clinical trial. Test subjects typically receive the most effective healthcare possible for their Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery  Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery
Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery
For Condition: Pain,unspecified adult solid tumor, protocol specific
Status: Not yet recruiting
Sponsor(s): North Central Cancer Treatment Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: A lidocaine patch may be effective in relieving numbness, tingling, and other symptoms of neuropathy. It is not yet known whether a lidocaine patch is effective in treating neuropathy in patients who have undergone surgery for cancer. PURPOSE: Randomizedphase III trial to study the effectiveness of a lidocaine patch in relieving numbness, tingling, and other symptoms of neuropathy in patients who have undergone surgery for cancer.
Details: OBJECTIVES: - Determine whether a lidocaine patch vs placebo improves postsurgical neuropathic pain in cancer patients. - Compare the toxic effects of these regimens in these patients. - Compare the effect of these regimens on mood states, functional abilities, and overall quality of life of these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to etiology of pain (breast surgery vs lung surgery vs amputation vs other), duration of pain (1-3 months vs 4-6 months vs more than 6 months), and current analgesic regimen (opioids [including tramadol] vs antidepressants vs anticonvulsants vs combination vs other). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive a lidocaine transdermal patch (up to 3 patches) applied directly to the painful area for 18 hours once daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity. At the end of week 4, patients cross over to arm II. - Arm II: Patients receive a placebo transdermal patch applied to the painful area as in arm I. At the end of week 4, patients cross over to arm I. Pain and quality of life are assessed at baseline and weekly for 8 weeks. Patients are followed at 3-7 days. PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Underwent breast or lung surgery, chest wall resection, amputation, or other surgical procedure for cancer diagnosis or treatment - Experiencing persistent pain for at least 1 month - Pain must have neuropathic features (e.g., burning, shooting, stabbing, tingling, or pain from light touch) - Anatomically related to the surgical site and compatible with nerve injury - Pain rating of at least 4 out of 10 on the pain scale - No pain of multiple etiologies at the proposed treatment site (e.g., pain of neuropathic and muscular or skeletal origin) - Painful area must be no larger than can be covered by 3 lidocaine patches* NOTE: *Each patch size is 5.5 x 4 inches - No skin disease, breakdown, infection, or extreme thinning at the site of pain - No skin or soft tissue malignancy in the painful area PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - At least 6 months Hematopoietic - Not specified Hepatic - AST no greater than 2 times upper limit of normal Renal - Not specified Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Able to understand and complete questionnaires - No recent history of or concurrent drug or alcohol abuse - No mental or psychiatric condition that would preclude giving informed consent - No history of allergic reaction or intolerance to lidocaine or other amide local anesthetics (e.g., bupivicaine) PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - More than 6 weeks since prior neurotoxic chemotherapy* - No concurrent neurotoxic chemotherapy* NOTE: *Including taxanes (e.g., paclitaxel or docetaxel), platinum-based compounds (e.g., cisplatin or carboplatin), or vinca alkaloids (e.g., vincristine or vinblastine) Endocrine therapy - More than 7 days since prior topical corticosteroids to the painful area - No new corticosteroids may be initiated during study participation Radiotherapy - No concurrent radiotherapy to the painful area Surgery - See Disease Characteristics Other - More than 6 weeks since other prior neurotoxic substances - More than 7 days since other prior topical medications to the painful area (including capsaicin) - No change in current analgesic regimen within the past 10 days - No new analgesic or adjuvant drugs (e.g., antidepressants, anticonvulsants, or anxiolytics) may be initiated during study participation - Concurrent stable doses of nonopioid, opioid, and adjuvant analgesic drugs are allowed (including antidepressants or anticonvulsants) - No concurrent class I antiarrhythmic drugs (e.g., tocainide and mexiletine) - No other concurrent neurotoxic substances - Concurrent skin lubricants and sunscreen are allowed provided they are not heavily applied
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GilbertWong, Study Chair, Mayo Clinic Cancer Center
Additional Information:
Study ID Numbers: CDR0000288824; NCCTG-N01CB
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00058357
Other Pain Studies:
1. Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
2. Voriconazole With or Without Interferon gamma in Treating Patients With Aspergillosis or Other Fungal Infections
3. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
4. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
5. 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Related Studies:
Other Pain Clinical Trials
Other Clinical Trials
Other Clinical Trials
Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery
|
|
|
|
|
|
|
|
